- Home
- HBB vs SWKH Comparison
HBB vs SWKH Comparison
Compare HBB & SWKH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HBB
- SWKH
- Stock Information
- Founded
- HBB 1904
- SWKH 1996
- Country
- HBB United States
- SWKH United States
- Employees
- HBB N/A
- SWKH N/A
- Industry
- HBB Home Furnishings
- SWKH Diversified Financial Services
- Sector
- HBB Consumer Discretionary
- SWKH Finance
- Exchange
- HBB Nasdaq
- SWKH Nasdaq
- Market Cap
- HBB 196.2M
- SWKH 175.5M
- IPO Year
- HBB 2017
- SWKH 1999
- Fundamental
- Price
- HBB $14.55
- SWKH $16.12
- Analyst Decision
- HBB
- SWKH Strong Buy
- Analyst Count
- HBB 0
- SWKH 1
- Target Price
- HBB N/A
- SWKH $18.00
- AVG Volume (30 Days)
- HBB 25.2K
- SWKH 64.7K
- Earning Date
- HBB 10-29-2025
- SWKH 11-13-2025
- Dividend Yield
- HBB 3.30%
- SWKH N/A
- EPS Growth
- HBB N/A
- SWKH 55.18
- EPS
- HBB 2.35
- SWKH 1.41
- Revenue
- HBB $631,318,000.00
- SWKH $37,409,000.00
- Revenue This Year
- HBB N/A
- SWKH $52.93
- Revenue Next Year
- HBB N/A
- SWKH N/A
- P/E Ratio
- HBB $6.20
- SWKH $11.42
- Revenue Growth
- HBB N/A
- SWKH 47.31
- 52 Week Low
- HBB $12.72
- SWKH $12.00
- 52 Week High
- HBB $31.12
- SWKH $17.90
- Technical
- Relative Strength Index (RSI)
- HBB 47.13
- SWKH 58.76
- Support Level
- HBB $14.48
- SWKH $16.12
- Resistance Level
- HBB $15.20
- SWKH $16.62
- Average True Range (ATR)
- HBB 0.57
- SWKH 0.36
- MACD
- HBB -0.02
- SWKH -0.02
- Stochastic Oscillator
- HBB 35.05
- SWKH 51.71
About HBB Hamilton Beach Brands Holding Company
Hamilton Beach Brands Holding Co, through its subsidiaries, is engaged in consumer, commercial, and specialty small appliances and specialty retail. It designs, markets, and distributes small branded electric household and specialty housewares small appliances, as well as commercial products for restaurants, bars, and hotels. It has two operating segments Home and Commercial Products and Health.
About SWKH SWK Holdings Corporation
SWK Holdings Corp is a healthcare capital provider. The company offers financing solutions to various life science companies, institutions, and inventors. It involves monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. Through its wholly-owned subsidiary, it also provides non-discretionary investment advisory services to institutional clients. The company's operating segments are Finance Receivables and Pharmaceutical Development Services. It generates maximum revenue from the Finance Receivables segment.